Investor Relations - Curis

May 30, 2013

Curis to Present at the Jefferies 2013 Global Healthcare Conference

LEXINGTON, Mass., May 30, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
May 22, 2013

Curis to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference

LEXINGTON, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
May 16, 2013

Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting

LEXINGTON, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
May 11, 2013

Curis to Present at the 2013 Wells Fargo Securities Healthcare Conference

LEXINGTON, Mass., June 11, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...
May 9, 2013

Curis Announces Approval of Erivedge(R) in Australia

Expands Global Erivedge Patient Access and Commercial Opportunity

LEXINGTON, Mass., May 10, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today...

Show per page